Consortium Members

What is the Dementia Consortium?

The Dementia Consortium supports collaborative target validation and drug discovery projects from academia and SMEs. We offer a unique collaborative model bringing together the charity and industry sectors to help accelerate development of therapies for novel dementia targets.

What do we offer?

The Dementia Consortium provides drug discovery resources, project management, industry expertise and tools as well as full funding support for projects. We can support small molecule or antibody-based strategies and aim to generate tools to achieve preclinical target validation. Our ultimate goal is to progress successful projects from laboratories towards the clinic.

Applications Open

Applications to collaborate with the Dementia Consortium are open on a rolling call basis and are reviewed six times per year. Please register your details to download the application form now.


This global initiative is open to:

• Academic researchers worldwide with a promising novel approach for a dementia therapy (including Alzheimer’s Disease, dementia with Lewy bodies, tauopathies, vascular dementia, frontotemporal dementia, and neurodegeneration-associated cognitive deficits).

• SME and small biotechs looking for further preclinical target validation of a new therapeutic small molecule or antibody

If you are not sure if your project is eligible or require more information please get in touch with us.

Apply Here

24th NOVEMBER 2015

The case for the Dementia Consortium

Neurodegenerative diseases that cause dementia are our biggest medical challenge. Dementia affects 820,000 people in the UK today and nearly 40 million worldwide. As populations age, the worldwide prevalence of dementia is expected to double every twenty years. Millions of lives will be blighted by these diseases.

As well as the enormous social cost, neurodegenerative disease carries an enormous economic impact. In the UK alone, dementia has an economic cost of £23bn, which is greater than heart disease and cancer combined.

The Dementia Consortium is focused on fast-tracking new treatments to find an answer to the neurodegenerative diseases that cause dementia.